
    
      The investigators propose to contact and interact with all patients with plasma cell
      dyscrasias in the State of Ohio (and all patients diagnosed or treated at Ohio State Medical
      Center) for both surveillance and research purposes in order to develop interventions
      targeted to decrease their morbidity and mortality.
    
  